GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (GREY:ARBQY) » Definitions » Shiller PE Ratio

Aurobindo Pharma (Aurobindo Pharma) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aurobindo Pharma Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurobindo Pharma Shiller PE Ratio Historical Data

The historical data trend for Aurobindo Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Shiller PE Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.59 19.83 14.06 9.82 19.08

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.82 13.24 16.34 19.05 19.08

Competitive Comparison of Aurobindo Pharma's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Shiller PE Ratio falls into.



Aurobindo Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aurobindo Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Aurobindo Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/153.0345*153.0345
=0.000

Current CPI (Mar. 2024) = 153.0345.

Aurobindo Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.119 94.103 0.194
201409 0.105 96.780 0.166
201412 0.105 96.780 0.166
201503 0.111 97.163 0.175
201506 0.127 99.841 0.195
201509 0.117 101.753 0.176
201512 0.140 102.901 0.208
201603 0.142 102.518 0.212
201606 0.149 105.961 0.215
201609 0.156 105.961 0.225
201612 0.146 105.196 0.212
201703 0.138 105.196 0.201
201706 0.137 107.109 0.196
201709 0.207 109.021 0.291
201712 0.158 109.404 0.221
201803 0.139 109.786 0.194
201806 0.115 111.317 0.158
201809 0.144 115.142 0.191
201812 0.172 115.142 0.229
201903 0.000 118.202 0.000
201906 0.000 120.880 0.000
201909 0.000 123.175 0.000
201912 0.000 126.235 0.000
202003 0.000 124.705 0.000
202006 0.000 127.000 0.000
202009 0.000 130.118 0.000
202012 0.000 130.889 0.000
202103 0.000 131.771 0.000
202106 0.000 134.084 0.000
202109 0.000 135.847 0.000
202112 0.000 138.161 0.000
202203 0.000 138.822 0.000
202206 0.000 142.347 0.000
202209 0.000 144.661 0.000
202212 0.000 145.763 0.000
202303 0.000 146.865 0.000
202306 0.000 150.280 0.000
202309 0.000 151.492 0.000
202312 0.000 152.924 0.000
202403 0.000 153.035 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurobindo Pharma  (GREY:ARBQY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aurobindo Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (Aurobindo Pharma) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (Aurobindo Pharma) Headlines